Diabetic Retinopathy And Non Endocrine Fibroblast Growth...

Diabetic retinopathy is induced by changes in retinal vasculature due to diabetic pathologies. Studies have shown endocrine fibroblast growth factor-21(FGF21) and non-endocrine fibroblast growth factor-1(FGF1) have therapeutic potential by increasing insulin sensitivity in vivo through unresolved mechanisms. To investigate this effect within the retina, exogenous FGF1(0-100ng/mL) and FGF21(0-100ng/mL) were administered to the murine-photoreceptor cell line, 661W. FGF1(p0.05), with a high dose restorative effect for both FGFs. Results on the effects of FGFs on scar tissue is pending. FGF1 and FGF21 demonstrate therapeutic potential in type-2 diabetic retina. Introduction The global presence of type-2 diabetes, which results when insulin-producing beta cells cannot compensate for rising insulin resistance, has risen constantly.In 2014, 9 percent of the adults worldwide had diabetes, and of those with diabetes, 90 percent had type 2 diabetes (World Health Organization, 2014). Not only has this global phenomenon has influenced other countries but it also has increased prevalence of obesity and insulin resistance in the United States,affecting 29.1 million people with diabetes (National Diabetes Statistics Report, 2014). The current treatments for diabetes, such as Thiazolidinediones, are highly effective oral medications with detrimental side effects including congestive heart failure, bone loss and weight gain(Suh et al. 2014). There is several evidence that fibroblast